2025-03-05 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis

**0) Executive Summary:** Eli Lilly and Co. (LLY) is a leading pharmaceutical company.  This report analyzes LLY's performance against the S&P 500 (VOO), considering price movements, financial statements, and key indicators.  LLY shows significantly higher returns than VOO, but also higher volatility.

**1) Performance Comparison:**

LLY has significantly outperformed the S&P 500 (VOO).  The cumulative return for LLY is 664.05%, while VOO's is 108.99%. The difference is 555.1%, placing it at the 88th percentile of historical relative performance compared to VOO (considering the range between minimum and maximum historical differences).  This suggests a strong outperformance historically, but this is not guaranteed to continue.

**Alpha and Beta Analysis:**

The provided data shows a consistently positive alpha, indicating LLY has generated returns exceeding what would be expected based on its beta (market risk). Beta has remained relatively stable around 0.3, showing lower than average market risk.  However, it's important to note that past performance is not indicative of future results.  The CAGR (Compound Annual Growth Rate) has been exceptionally strong over the observed periods, increasing significantly over time.  The maximum drawdown (MDD) shows substantial volatility, especially in the recent years, requiring consideration of risk tolerance.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 9.0% | 4.3% | -19.0% | 0.0 | 67.7 |
| 2016-2018  | 47.0% | 4.3% | 29.0% | 0.0 | 95.1 |
| 2017-2019  | 60.0% | 8.8% | 29.0% | 1.0 | 110.5 |
| 2018-2020  | 90.0% | 11.2% | 62.0% | 0.3 | 144.7 |
| 2019-2021  | 145.0% | 11.2% | 74.0% | 0.2 | 240.4 |
| 2020-2022  | 196.0% | 11.2% | 187.0% | 0.2 | 322.7 |
| 2021-2023  | 300.0% | 10.8% | 277.0% | 0.3 | 519.3 |
| 2022-2024  | 396.0% | 11.1% | 363.0% | 0.3 | 692.2 |
| 2023-2025  | 421.0% | 11.1% | 371.0% | 0.3 | 818.3 |


**2) Recent Price Movement:**

* **Closing Price:** $911.06
* **Previous Close:** $929.72
* **Change:** -$1.66 (a decrease of approximately -1.78%)
* **5-day Moving Average:** $916.32
* **20-day Moving Average:** $878.19
* **60-day Moving Average:** $814.90

The price is currently below the 5-day and 20-day moving averages, suggesting a short-term bearish trend. However, it is still above the 60-day moving average, indicating a longer-term uptrend.  The recent price drop is a relatively small move compared to the overall trend.

**3) Technical Indicators:**

* **RSI (Relative Strength Index):** 64.96 – This suggests the stock is neither overbought nor oversold, but approaching potentially overbought territory.
* **PPO (Percentage Price Oscillator):** 0.26 – A positive PPO indicates upward momentum.
* **20-Day Relative Divergence:** +1.5 – Suggests short-term upward momentum.
* **Expected Return (vs. S&P 500):** 82.4% –  This high expected return is based on long-term investment and historic performance.  This high expectation reflects the substantial historical outperformance, but it's crucial to remember future performance is uncertain.

**4) Recent Earnings Analysis:**

The earnings data shows some volatility. While there are periods of strong EPS and revenue growth, there's also a notable loss reported.  A more in-depth analysis of the underlying reasons for these fluctuations is needed to draw definitive conclusions.

| Date       | EPS  | Revenue        |
|------------|------|-----------------|
| 2024-10-30 | $1.08 | $11.44 B       |
| 2024-08-08 | $3.29 | $11.30 B       |
| 2024-04-30 | $2.49 | $8.77 B        |
| 2023-11-02 | -$0.06| $9.50 B        |
| 2024-10-30 | -$0.06| $9.50 B        |


**5) Financial Information:**

The financial data reveals consistently high profit margins and ROE (Return on Equity), suggesting strong profitability and efficiency.  However, there are fluctuations in both revenue and equity from quarter to quarter.  Further investigation into the factors influencing these fluctuations would be beneficial.

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $13.53B | 82.24%       |
| 2024-09-30 | $11.44B | 81.02%       |
| 2024-06-30 | $11.30B | 80.80%       |
| 2024-03-31 | $8.77B  | 80.91%       |
| 2023-12-31 | $9.35B  | 80.88%       |


**Capital and Profitability:**

| Quarter | Equity   | ROE     |
|---------|----------|---------|
| 2024-12-31 | $14.19B | 31.07%  |
| 2024-09-30 | $14.24B | 6.81%   |
| 2024-06-30 | $13.56B | 21.88%  |
| 2024-03-31 | $12.81B | 17.51%  |
| 2023-12-31 | $10.77B | 20.33%  |


**6) Overall Analysis:**

LLY has demonstrated exceptionally strong performance relative to the S&P 500, evidenced by significantly higher cumulative returns and consistently positive alpha.  However, this outperformance is accompanied by considerable volatility, as shown by the MDD. The recent price action suggests a slight short-term bearish trend, but the longer-term outlook remains positive based on the 60-day moving average.  High profit margins and ROE indicate strong financial health.  However,  a deeper dive into the causes of earnings fluctuations and quarterly variations in revenue and equity is needed for a more comprehensive assessment.  The high projected return should be viewed with caution,  as it relies on past performance being an indicator of future success, which is not guaranteed.  Investors should consider their own risk tolerance before investing.
